Proteome

Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Lung cancer, Survival, NSCLC, Immunotherapy, Colorectal cancer, Central nervous system, Patient, CNS, Neoplasm, AACR, PDX, Clinical trial, Pancreatic cancer, Cancer, CRC, Metastasis, Proteome, PD-1, Pharmaceutical industry

- The Phase 1/2 PROSPER clinical trial is currently evaluating FMC-376 in patients with KRASG12C cancers, regardless of prior KRAS inhibitor therapy BOSTON and SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical-stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today presented new preclinical data on its KRASG12C inhibitor, FMC-376, at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. The new findings demonstrate FMC-376’s potential to overcome known mechanisms of innate and acquired resistance and in a CNS model of metastasis as a monotherapy and increase the efficacy of PD-1 immunotherapy in combination.

Key Points: 
  • “These data demonstrate FMC-376’s unmatched potential to overcome over 90 percent of known resistance mechanisms, including those cancers that have become refractory to approved KRAS inhibitors.
  • The differentiated dual direct mechanism of action of FMC-376 offers the potential to overcome the resistance and lack of response seen with current KRASG12C single-acting treatments.
  • These results reinforce that FMC-376 has the potential to overcome limitations of single-acting KRASG12C inhibitors.
  • The combination of FMC-376 with an immune checkpoint inhibitor also leads to an increased response and survival in preclinical models.

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Retrieved on: 
Thursday, April 4, 2024
Plasma, NSCLC, Disease, Partnership, Inflammation, Patient, Biomarker, Research, Acquisition, Protein, Proteomics, Biology, Medicine, AACR, Chemokine, Society, Cytokine, Mass spectrometry, Fluid mechanics, Proteome, Annual general meeting, Pharmaceutical industry

This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.

Key Points: 
  • This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s cutting-edge immunoassays.
  • Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.
  • Research Collaboration: Biognosys and Alamar will embark on a joint research initiative to explore plasma biology.
  • Oliver Rinner, Ph.D., Founder and CEO of Biognosys, expressed enthusiasm about the collaboration: “We are excited to join forces with Alamar to advance proteomics research.

The Second International Conference on Single-cell and Spatial Omics (TICSSO-2) : showcasing the state-of-the-art bioscience achievements

Retrieved on: 
Tuesday, April 9, 2024
Shenzhen University, Molecular biology, Immunology, Nature Methods, Advanced technology, Proteome, Ageing, Speech, Genesis (journal), Data analysis, Southern Medical University, Neuroscience, Translation, Human Cell Atlas, Nature Communications, Biochemistry, Neurology, Communication, Transcriptome, Genetics, Research, Genome, Epigenome, Immunity, Microbiology, Metabolome, Diagnosis, Peking University, Health, Conference, GSA, Executive, Cancer, Fudan University, Reproduction, Biology, National academy, Zhejiang University, Medicine

SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.

Key Points: 
  • SHENZHEN, China, April 9, 2024 /PRNewswire/ -- The Second International Conference on Single-cell and Spatial Omics (TICSSO-2), was held from March 29th to April 1st, 2024, in Shenzhen, China.
  • With the theme "Technologic Innovation, Scientific Discovery, Translational Application", TICSSO-2 focused on the latest advances in single-cell and spatial omics.
  • On March 31st and April 1st were four online international forums, with one specifically for young researchers.
  • TICSSO-2 is hailed as the largest, most influential, and highest academic conference in the field of single-cell and spatial omics in the world.

Atomwise Publishes Results from 318-Target Study Showcasing AtomNet AI Platform’s Ability to Discover Structurally Novel Chemical Matter

Retrieved on: 
Tuesday, April 2, 2024
Research, Technology, Neurology, Health Technology, Biotechnology, Managed Care, Pharmaceutical, Health, Science, Artificial Intelligence, AIMS, Biochemistry, Disease, Executive, University, HTS, Patient, AI, Scientific Reports, OTUD7B, IND, PPM1D, Biology, Biophysics, Cancer, Pharmacokinetics, TYK2, Development, Probability, Artificial intelligence, Proteome, Pharmaceutical industry

Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter.

Key Points: 
  • Atomwise announced today results from the AIMS (Artificial Intelligence Molecular Screen) initiative that establish the AtomNet AI Platform as a viable alternative to high-throughput screening (HTS) and verify its ability to consistently discover structurally novel chemical matter.
  • AtomNet also showed a remarkable ability to discover novel chemical matter, averaging over seven structurally distinct bioactive compounds per target.
  • Developed by Atomwise, AtomNet was the first deep neural network designed to predict the bioactivity of small molecules in structure-based drug discovery.
  • Our belief is structurally novel chemical matter increases the likelihood of developing first-in-class and best-in-class medicines that have the potential to transform patient care.

Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

Retrieved on: 
Thursday, April 4, 2024
Plasma, NSCLC, Disease, Partnership, Inflammation, Patient, Biomarker, Research, Acquisition, Protein, Proteomics, Biology, Medicine, AACR, Chemokine, Society, Cytokine, Mass spectrometry, Fluid mechanics, Proteome, Annual general meeting, Pharmaceutical industry

Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.

Key Points: 
  • Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.
  • Research Collaboration: Biognosys and Alamar will embark on a joint research initiative to explore plasma biology.
  • Oliver Rinner, Ph.D., Founder and CEO of Biognosys, expressed enthusiasm about the collaboration: "We are excited to join forces with Alamar to advance proteomics research.
  • This partnership underscores the commitment of both companies to scientific excellence and their shared vision of advancing precision medicine through innovative technologies.

Integral Molecular Achieves ISO 9001 Certification for its Membrane Proteome Array Service

Retrieved on: 
Wednesday, March 27, 2024
Certification, Culture, Biotechnology, NDA, Integral, MPA, QMS, Antibody, IS0, Drug development, Safety, Therapy, ISO, Collection, FDA, BLA, Proteome

PHILADELPHIA, March 27, 2024 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery and characterization, proudly announces the achievement of IS0 9001 certification for the quality systems and processes used in its Membrane Proteome Array™ (MPA) specificity testing services. This platform is a vital tool for biotechnology and pharmaceutical companies to assess the safety and off-target reactivity of therapeutic antibodies and other biologics.

Key Points: 
  • ISO 9001 certification validates Integral Molecular's quality processes for its Membrane Proteome Array, reflecting the company's commitment to quality.
  • PHILADELPHIA, March 27, 2024 /PRNewswire/ -- Integral Molecular, a leader in antibody discovery and characterization, proudly announces the achievement of IS0 9001 certification for the quality systems and processes used in its Membrane Proteome Array™ (MPA) specificity testing services.
  • "Integral Molecular has maintained a culture of commitment to delivering exceptional quality products and services for over 20 years.
  • As the industry increasingly relies on MPA specificity profiling to support drug safety, we are delighted to receive ISO 9001 Certification to reinforce our commitment to quality for our customers."

Frontier Medicines to Present Preclinical Data at the American Association for Cancer Research Annual Meeting 2024

Retrieved on: 
Wednesday, March 6, 2024
Proteome, NCT, Safety, Pharmacokinetics, AACR, Pharmaceutical industry

BOSTON and SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced new preclinical data for FMC-376, a first-in-class direct dual inhibitor of ON+OFF KRASG12C currently being explored in a Phase 1/2 trial, will be shared at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • BOSTON and SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a clinical stage precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced new preclinical data for FMC-376, a first-in-class direct dual inhibitor of ON+OFF KRASG12C currently being explored in a Phase 1/2 trial, will be shared at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024.
  • FMC-376 was discovered by applying the Frontier™ Platform to directly engage both ON+OFF KRASG12C with exquisite selectivity.
  • The differentiated dual direct mechanism of action of FMC-376 offers the potential to overcome the lack of response and resistance seen with current KRASG12C single-acting treatments.
  • For more information on the PROSPER trial, please visit clinicaltrials.gov .

Frontier Medicines to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, February 27, 2024
Proteome, Medicine, Conference

BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will participate in the upcoming Evercore ISI Emerging Private Biotech Conference, TD Cowen Annual Health Care Conference, and Leerink Partners Global Biopharma Conference.

Key Points: 
  • BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced that Chris Varma, Ph.D., Frontier’s co-founder, chairman, and CEO, will participate in the upcoming Evercore ISI Emerging Private Biotech Conference, TD Cowen Annual Health Care Conference, and Leerink Partners Global Biopharma Conference.

Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline

Retrieved on: 
Thursday, February 22, 2024
NSCLC, NCT, Galapagos NV, Euronext, Safety, Pharmacokinetics, Medicine, Patient, Acceleration, Proteome, Clinical trial, Science, Medication, Pharmaceutical industry

BOSTON and SOUTH SAN FRANCISCO, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance transformational therapies against otherwise undruggable disease-causing targets, today announced the close of an oversubscribed $80 million Series C financing. The financing was co-led by Deerfield Management Company and Droia Ventures, with significant participation from Galapagos NV (Euronext & NASDAQ: GLPG) as a strategic investor, and contributions from new and existing investors including DCVC Bio, MPM Capital, and RA Capital Management. This Series C financing brings the total capital raised since Frontier’s founding to $235.5 million.

Key Points: 
  • This Series C financing brings the total capital raised since Frontier’s founding to $235.5 million.
  • “Frontier Medicines is a leading chemoproteomics company with a unique technology platform and a pipeline of potential best-in-class assets that fit with Galapagos’ precision oncology R&D approach.
  • The participation in Frontier Medicines' Series C round aligns with our innovation acceleration strategy to bring transformational medicines to patients around the world.”
    Financing proceeds will support the advancement of multiple wholly-owned pipeline programs into clinical studies, including FMC-376.
  • “Today we mark the first participant dosed with a therapeutic candidate born from the Frontier™ Platform, alongside a financing that affirms continued strong investor support.

Quantum-Si and Researchers to Highlight the Power of Next-Generation Protein Sequencing™ on Platinum® at US HUPO Conference

Retrieved on: 
Thursday, March 7, 2024
Research, Technology, Other Health, Biotechnology, Hardware, Pharmaceutical, Health, Science, Oncology, Other Science, Molecule, Breakfast, PTM, Booth, Protein sequencing, Conference, Doctor of Philosophy, Protein, Johns Hopkins University, Mass spectrometry, Proteomics, Proteome, Assistant professor, Body modification, Hyatt Regency Portland, Microscope

WHAT: The Protein Sequencing Company™, Quantum-Si Incorporated , will showcase its Next-Generation Protein Sequencing™ instrument, Platinum®, and recent enhancements at the 20th Anniversary US HUPO Conference in Portland, Oregon on March 9-13.

Key Points: 
  • WHAT: The Protein Sequencing Company™, Quantum-Si Incorporated , will showcase its Next-Generation Protein Sequencing™ instrument, Platinum®, and recent enhancements at the 20th Anniversary US HUPO Conference in Portland, Oregon on March 9-13.
  • Additionally, researchers will present data from Platinum and highlight how protein sequencing on the benchtop instrument is providing deeper insights into proteins through streamlined workflows.
  • WHY: Quantum-Si brings the groundbreaking power of single-molecule proteomics with the first-to-market Next-Generation Protein Sequencer™, the Platinum instrument, to every lab, everywhere.
  • WHERE: The 2024 US HUPO Conference is being held at the Hyatt Regency Portland, 375 NE Holladay St, Portland, OR 97232